Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 14/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572348 | 1.00 | GPR17 (0.72) | GPR17P2RY2TSHRACHECYP1A2 | |
| SCHEMBL7335028 | 0.88 | GPR17 (0.69) | GPR17P2RY2 | |
| SCHEMBL8818922 | 0.86 | GPR17 (0.65) | GPR17P2RY2TSHRACHE | |
| SCHEMBL8819570 | 0.85 | GPR17 (0.61) | GPR17P2RY2TSHRACHE | |
| SCHEMBL29155254 | 0.85 | GPR17 (0.56) | GPR17P2RY2 | |
| SCHEMBL29155194 | 0.85 | GPR17 (0.59) | GPR17P2RY2 | |
| Dinitrophenylene SCHEMBL27503833 | 0.82 | CYP1A2 (0.57) | GPR17P2RY2TSHRACHECYP1A2 | |
| SCHEMBL2234824 | 0.81 | HSP90AA1 (0.63) | GPR17ACHE | |
| SCHEMBL29413045 | 0.81 | KMT2A (0.54) | GPR17P2RY2TSHRACHE | |
| SCHEMBL1061125 | 0.81 | HSP90AA1 (0.63) | GPR17ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213637-A | Synthetic method of high-molecular-weight polylactic acid | 江苏睿安应用生物技术股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-121578590-A | Composition for forming lower layer film of patterning material and lower layer film of patterning material | 珠海基石科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| CN-117986406-A | Preparation method and application of mono 2-O-p-toluenesulfonyl-beta-cyclodextrin ester | 南昌大学 | 2024-05-07 | — | — | CN | disclosed |
| EP-4361162-A2 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | Takasago International Corporation (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-114213637-A | Synthetic method of high-molecular-weight polylactic acid | 江苏睿安应用生物技术股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-7375095-B2 | Sugar derivative | KABASHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20040254367-A1 | Sugar derivative | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENYUJO (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1460081-A1 | SUGAR DERIVATIVE | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-0518930-A4 | CYCLODEXTRIN COMPOSITIONS AND METHODS FOR PHARMACEUTICAL AND INDUSTRIAL APPLICATIONS | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0518930-A1 | CYCLODEXTRIN COMPOSITIONS AND METHODS FOR PHARMACEUTICAL AND INDUSTRIAL APPLICATIONS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013100-A1 | CYCLODEXTRIN COMPOSITIONS AND METHODS FOR PHARMACEUTICAL AND INDUSTRIAL APPLICATIONS | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1991-09-05 | — | — | WO | disclosed |
| US-4777250-A | LOW MOLECULAR WEIGHT; STABLE | NORTHWESTERN UNIVERSITY (US) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TDO2, SCO2, DUOX1 | GPR17 2714/4885P2RY2 1104/4885TSHR 4075/4885 |
| US-20040254367-A1 | Sugar derivative | FUT5, FUT6, MAN1B1 | GPR17 1696/4885P2RY2 1094/4885TSHR 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.